meRfi®-GM
Farnesoid X receptor (FXR / NR1H4) agonists
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Key features:
Agonists activate Farnesoid X Receptor (FXR / NR1H4)
In enterocytes conjugated bile acids activate FXR
Activation of Farnesoid X receptor (FXR / NR1H4) favors the expression of Occludin, Claudin 1, and ZO1, maintaining [epithelial barrier integrity](brain://x8ztgCp9RU6lQnz1P-5Q8g/EpithelialBarrierIntegrityMuco…
References (Sources)
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
- Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response
- FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice
- Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
- Key Signaling in Alcohol-Associated Liver Disease: The Role of Bile Acids
- Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology